PHAT short interest
Phathom Pharmaceuticals Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 10,109,151 |
|---|---|
| Change vs prior report | -48,058 (-0.5%) |
| Change over six months | -5.0% |
| Days to cover | 7.36 (sector: 3.78) |
| Average daily volume | 1,373,184 |
| Rank in Healthcare | #222 of 922 by days to cover |
PHAT short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 10,109,151 | -0.5% | 7.36 | 1,373,184 |
| 2026-09-15 | 10,157,209 | -6.2% | 9.11 | 1,114,723 |
| 2026-08-31 | 10,823,977 | -8.1% | 11.01 | 983,432 |
| 2026-08-14 | 11,773,979 | -11.7% | 6.87 | 1,713,950 |
| 2026-07-31 | 13,327,316 | +9.9% | 8.70 | 1,531,462 |
| 2026-07-15 | 12,121,682 | +1.1% | 9.00 | 1,347,515 |
| 2026-06-30 | 11,993,590 | +7.4% | 11.67 | 1,028,056 |
| 2026-06-15 | 11,162,619 | +7.8% | 10.36 | 1,076,980 |
| 2026-05-29 | 10,352,426 | +0.6% | 9.41 | 1,099,616 |
| 2026-05-15 | 10,288,317 | +5.7% | 8.68 | 1,185,608 |
| 2026-04-30 | 9,736,465 | +2.5% | 5.88 | 1,655,203 |
| 2026-04-15 | 9,502,963 | -10.7% | 9.92 | 958,012 |
| 2026-03-31 | 10,637,936 | -8.8% | 9.23 | 1,152,562 |
| 2026-03-13 | 11,657,728 | +4.4% | 10.93 | 1,066,950 |
| 2026-02-27 | 11,169,289 | -4.7% | 9.81 | 1,138,069 |
| 2026-02-13 | 11,718,291 | +2.8% | 14.85 | 789,036 |
| 2026-01-30 | 11,396,304 | +8.3% | 10.88 | 1,047,466 |
| 2026-01-15 | 10,523,193 | -2.4% | 6.48 | 1,624,876 |
| 2025-12-31 | 10,780,383 | -15.0% | 10.51 | 1,025,858 |
| 2025-12-15 | 12,677,843 | -0.5% | 15.98 | 793,128 |
| 2025-11-28 | 12,739,028 | -2.6% | 16.13 | 789,768 |
| 2025-11-14 | 13,078,808 | -3.6% | 14.33 | 912,810 |
| 2025-10-31 | 13,566,849 | -4.0% | 13.59 | 998,568 |
| 2025-10-15 | 14,125,695 | +7.0% | 9.27 | 1,524,284 |
| 2025-09-30 | 13,199,013 | -5.7% | 10.71 | 1,232,883 |
import finzdata as yf
yf.Ticker("PHAT").short_interest # every report since 2017
yf.Client().short_interest(["PHAT"], start="2018-01-01")Healthcare short interest · PHAT price history · Who owns PHAT · All short interest